Candidate Drug designated within the Medivir Tibotec Collaboration
Advertisement
The hepatitis C Virus (HCV) collaboration of Medivir AB with Tibotec Pharmaceuticals Ltd has recently designated a Candidate Drug (CD). The aim of the research collaboration is to identify and develop orally active inhibitors of the HCV protease NS3/4A. The collaboration was initiated in November 2004 and attaining a CD designation represents an important step on the way towards clinical development.
Separately, the first milestone for preclinical development has been reached in the program, triggering a milestone payment to Medivir of EUR5m.